pioglitazone/metformin/dapagliflozin (BR3003) / Boryung Group - LARVOL DELTA

TELOS: A Phase IV Clinical Trial to Compare the Efficacy and Safety of Metformin+Sodium-Glucose Cotransporter 2 Inhibitor(SGLT2-i)+Thiazolidinedione (TZD) in Patients With Type 2 Diabetes (clinicaltrials.gov) - P4 | N=204 | Recruiting | Sponsor: Boryung Pharmaceutical Co., Ltd | Not yet recruiting ➔ Recruiting

Enrollment open • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

TELOS: A Phase IV Clinical Study to Compared the Efficacy and Safety of Switching Metformin+SGLT2-i+DPP4-i to Metformin+SGLT2-i+TZD in Patients With Type 2 Diabetes (clinicaltrials.gov) - P4 | N=204 | Not yet recruiting | Sponsor: Boryung Pharmaceutical Co., Ltd

New P4 trial • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

A Study to Evaluate the Efficacy and Safety of Pioglitazone 15mg or 30mg Add-on in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin and Dapagliflozin (clinicaltrials.gov) - P3 | N=378 | Completed | Sponsor: Boryung Pharmaceutical Co., Ltd | Active, not recruiting ➔ Completed | Trial completion date: Oct 2022 ➔ Mar 2023

Trial completion • Trial completion date • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

A Study to Evaluate the Pharmacokinetics After Administration of BR3003 and Co-administration of BR3003B and BR3003C. (clinicaltrials.gov) - P1 | N=48 | Completed | Sponsor: Boryung Pharmaceutical Co., Ltd | Recruiting ➔ Completed

Trial completion • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

A Study to Evaluate the Pharmacokinetics After Administration of BR3003 and Co-administration of BR3003B and BR3003C. (clinicaltrials.gov) - P1 | N=46 | Recruiting | Sponsor: Boryung Pharmaceutical Co., Ltd

New P1 trial • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus